切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03): 180 -185. doi: 10.3877/cma.j.issn.1674-3903.2023.03.010

综述

肝移植治疗鸟氨酸氨甲酰转移酶缺乏症的研究进展
林冬妮, 万平, 夏强()   
  1. 200127 上海交通大学医学院附属仁济医院肝脏外科
    200127 上海交通大学医学院附属仁济医院肝脏外科;200127 上海市器官移植研究所;200127 上海市器官移植与免疫工程技术研究中心
  • 收稿日期:2023-04-21 出版日期:2023-06-25
  • 通信作者: 夏强
  • 基金资助:
    国家和省级重大疾病多学科合作诊疗能力建设项目(2020); 上海市"科技创新行动计划"医学创新研究专项项目(22Y21900400)

New progress in liver transplantation for ornithine transcarbamylase deficiency

Dongni Lin, Ping Wan, Qiang Xia()   

  1. Liver Department, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    Liver Department, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; Shanghai Institute of Organ Transplantation, Shanghai 200127, China; Shanghai Research Center of Organ Transplantation & Immune Engineering Technology, Shanghai 200127, China
  • Received:2023-04-21 Published:2023-06-25
  • Corresponding author: Qiang Xia

鸟氨酸氨甲酰转移酶(OTC)缺乏症(OTCD)是一种X连锁肝脏代谢遗传病,也是最常见的尿素循环障碍疾病。由于OTC基因缺陷引起OTC活性降低或缺失,患者出现血氨代谢障碍,临床表现为反复发作的高氨血症及神经系统损伤。对于保守治疗无效的患者,目前肝移植是唯一的治愈方法,可纠正患者代谢危象,提高其长期生存质量。本文针对OTCD患者的肝移植手术适应证和手术时机、手术方式和供者选择以及术后远期疗效三个方面,综述肝移植治疗OTCD的研究进展。

Ornithine transcarbamylase (OTC) deficiency (OTCD) is an X-linked genetic disorder caused by a genetic defect of OTC that results in disorders of ammonia metabolism, leading to recurrent hyperammonemia and neurological damage. For patients failed with conservative treatment, liver transplantation is currently the only curative method to correct the patient′s metabolic crisis and improve long-term survival quality. This article reviews the research progress of liver transplantation for OTCD in three aspects: indications and timing of liver transplantation, surgical approach and donor selection, and long-term postoperative outcomes.

1
孔元原,韩连书,杨艳玲,等. 鸟氨酸氨甲酰转移酶缺乏症诊治专家共识[J]. 浙江大学学报(医学版), 2020, 49(5): 539-547.
2
Seminara J, Tuchman M, Krivitzky L, et al. Establishing a consortium for the study of rare diseases: the Urea Cycle Disorders Consortium[J]. Mol Genet Metab, 2010, 100(Suppl 1): S97- S 105.
3
Donovan K, Guzman N. Ornithine transcarbamylase deficiency[M]. Treasure Island (FL): StatPearls, 2022.
4
Redant S, Empain A, Mugisha A, et al. Management of late onset urea cycle disorders-a remaining challenge for the intensivist?[J]. Ann Intensive Care, 2021, 11(1): 2.
5
Hertzog A, Selvanathan A, Halligan R, et al. A serendipitous journey to a promoter variant: the c.-106C>A variant and its role in late-onset ornithine transcarbamylase deficiency[J]. JIMD Rep, 2022, 63(4): 271-275.
6
Haberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230.
7
中国医师协会医学遗传医师分会临床生化专业委员会,中华医学会儿科学分会内分泌遗传代谢学组,中国妇幼保健协会儿童疾病和保健分会遗传代谢学组,等. 中国尿素循环障碍诊断治疗和管理指南[J]. 中华儿科杂志2022, 60(11): 1118-1126.
8
Enosawa S, Horikawa R, Yamamoto A, et al. Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: a novel source of hepatocytes[J]. Liver Transpl, 2014, 20(3): 391-393.
9
Meyburg J, Opladen T, Spiekerkotter U, et al. Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders[J]. J Inherit Metab Dis, 2018, 41(1): 81-90.
10
Smets F, Dobbelaere D, Mckiernan P, et al. Phase I/II trial of liver-derived mesenchymal stem cells in pediatric liver-based metabolic disorders: a prospective, open label, multicenter, partially randomized, safety study of one cycle of heterologous human adult liver-derived progenitor cells (HepaStem) in urea cycle disorders and Crigler-Najjar syndrome patients[J]. Transplantation, 2019, 103(9): 1903-1915.
11
Prieve MG, Harvie P, Monahan SD, et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency[J]. Mol Ther, 2018, 26(3): 801-813.
12
Baruteau J, Cunningham SC, Yilmaz BS, et al. Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys[J]. Mol Ther Methods Clin Dev, 2021, 23: 135-146.
13
De Sabbata G, Boisgerault F, Guarnaccia C, et al. Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector[J]. Mol Ther Methods Clin Dev, 2021, 20: 169-180.
14
Yang Y, Wang L, Bell P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice[J]. Nat Biotechnol, 2016, 34(3): 334-338.
15
Wang L, Yang Y, Breton C, et al. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency[J]. Sci Adv, 2020, 6(7): eaax5701.
16
Kim IK, Niemi AK, Krueger C, et al. Liver transplantation for urea cycle disorders in pediatric patients: a single-center experience[J]. Pediatr Transplant, 2013, 17(2): 158-167.
17
Kido J, Matsumoto S, Mitsubuchi H, et al. Early liver transplantation in neonatal-onset and moderate urea cycle disorders may lead to normal neurodevelopment[J]. Metab Brain Dis, 2018, 33(5): 1517-1523.
18
Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders[J]. Ann Neurol, 2019, 86(1): 116-128.
19
Kido J, Matsumoto S, Häberle J, et al. Role of liver transplantation in urea cycle disorders: report from a nationwide study in Japan[J]. J Inherit Metab Dis, 2021, 44(6): 1311-1322.
20
Wakiya T, Sanada Y, Mizuta K, et al. Living donor liver transplantation for ornithine transcarbamylase deficiency[J]. Pediatr Transplant, 2011, 15(4): 390-395.
21
Campeau PM, Pivalizza PJ, Miller G, et al. Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study[J]. Mol Genet Metab, 2010, 100 (Suppl 1): S84- S87.
22
Teufel U, Weitz J, Flechtenmacher C, et al. High urgency liver transplantation in ornithine transcarbamylase deficiency presenting with acute liver failure[J]. Pediatr Transplant, 2011, 15(6): E110- E115.
23
Gallagher RC, Lam C, Wong D, et al. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency[J]. J Pediatr, 2014, 164(4): 720-725.e6.
24
Largilliere C, Houssin D, Gottrand F, et al. Liver transplantation for ornithine transcarbamylase deficiency in a girl[J]. J Pediatr, 1989, 115(3): 415-417.
25
Takanashi J, Kurihara A, Tomita M, et al. Distinctly abnormal brain metabolism in late-onset ornithine transcarbamylase deficiency[J]. Neurology, 2002, 59(2): 210-214.
26
Fu XH, Hu YH, Liao JX, et al. Liver transplantation for late-onset ornithine transcarbamylase deficiency: a case report[J]. World J Clin Cases, 2022, 10(18): 6156-6162.
27
Jin X, Zeng X, Zhao D, et al. Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: a case report and review of the literature[J]. Brain Behav, 2022, 12(10): e2765.
28
Kido J, Matsumoto S, Häberle J, et al. Long-term outcome of urea cycle disorders: report from a nationwide study in Japan[J]. J Inherit Metab Dis, 2021, 44(4): 826-837.
29
Scharre S, Posset R, Garbade SF, et al. Predicting the disease severity in male individuals with ornithine transcarbamylase deficiency[J]. Ann Clin Transl Neurol, 2022, 9(11): 1715-1726.
30
Wakiya T, Sanada Y, Urahashi T, et al. Impact of enzyme activity assay on indication in liver transplantation for ornithine transcarbamylase deficiency[J]. Mol Genet Metab, 2012, 105(3): 404-407.
31
Kido J, Sugawara K, Sawada T, et al. Pathogenic variants of ornithine transcarbamylase deficiency: nation-wide study in Japan and literature review[J]. Front Genet, 2022, 13: 952467.
32
Nakamura K, Kido J, Matsumoto S, et al. Clinical manifestations and growth of patients with urea cycle disorders in Japan[J]. J Hum Genet, 2016, 61(7): 613-616.
33
Hong SK, Yi NJ, Yoon KC, et al. Outcomes of pediatric liver transplantation in Korea using two national registries[J]. J Clin Med, 2020, 9(11):3435.
34
Kasahara M, Sakamoto S, Horikawa R, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry[J]. Pediatr Transplant, 2014, 18(1): 6-15.
35
Morioka D, Kasahara M, Takada Y, et al. Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide english literature and 13 cases at Kyoto University[J]. Liver Transpl, 2005, 11(11): 1332-1342.
36
Dong C, Song Z, Meng X, et al. Successful living donor liver transplantation plus domino-auxiliary partial orthotopic liver transplantation for pediatric patients with metabolic disorders[J]. Pediatr Surg Int, 2020, 36(12): 1443-1450.
37
Morioka D, Kasahara M, Takada Y, et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders[J]. Am J Transplant, 2005, 5(11): 2754-2763.
38
Wakiya T, Sanada Y, Urahashi T, et al. Living donor liver transplantation from an asymptomatic mother who was a carrier for ornithine transcarbamylase deficiency[J]. Pediatr Transplant, 2012, 16(6): E196- E200.
39
Rahayatri TH, Uchida H, Sasaki K, et al. Hyperammonemia in ornithine transcarbamylase-deficient recipients following living donor liver transplantation from heterozygous carrier donors[J]. Pediatr Transplant, 2017, 21(1) :10.1111/petr.12848.
40
Batshaw ML, Robinson MB, Ye X, et al. Correction of ureagenesis after gene transfer in an animal model and after liver transplantation in humans with ornithine transcarbamylase deficiency[J]. Pediatr Res, 1999, 46(5): 588-593.
41
Lu D, Han F, Qiu W, et al. Clinical and molecular characteristics of 69 Chinese patients with ornithine transcarbamylase deficiency[J]. Orphanet J Rare Dis, 2020, 15(1): 340.
42
孙丽莹,朱志军. 尿素循环障碍的肝移植治疗[J]. 中国实用儿科杂志2021, 36(10): 768-771.
43
Huang HP, Chien YH, Huang LM, et al. Viral infections and prolonged fever after liver transplantation in young children with inborn errors of metabolism[J]. J Formos Med Assoc, 2005, 104(9): 623-629.
44
Ziogas IA, Wu WK, Matsuoka LK, et al. Liver transplantation in children with urea cycle disorders: the importance of minimizing waiting time[J]. Liver Transpl, 2021, 27(12): 1799-1810.
[1] 李丽, 何恩辉, 徐瑞芳, 易展雄, 朱志军, 孙丽莹, 魏林, 曲伟, 曾志贵, 刘颖, 钱林学. 超声造影在诊断儿童移植肝动脉闭塞中的作用[J]. 中华医学超声杂志(电子版), 2022, 19(07): 701-706.
[2] 徐烨, 李婧, 刘冉佳, 潘晨, 郭明星, 崔向丽. 2017至2021年中国95家医疗机构肝移植术后免疫抑制剂用药分析[J]. 中华移植杂志(电子版), 2023, 17(03): 134-139.
[3] 雷雪雪, 于颖, 李虹彦. 乙型肝炎肝硬化患者肝移植等待期应用多模式预康复优化项目的临床研究[J]. 中华移植杂志(电子版), 2023, 17(03): 158-163.
[4] 李君, 范铁艳, 牛鑫鑫, 陈虹. 肝移植后他克莫司致缺铁性贫血一例[J]. 中华移植杂志(电子版), 2023, 17(03): 169-170.
[5] 俞祺健, 杨喆, 郑树森. 预防肝癌肝移植术后肿瘤复发的研究现状及进展[J]. 中华移植杂志(电子版), 2023, 17(03): 171-179.
[6] 石晓萍, 老东辉, 王菁, 吕迁洲, 李晓宇, 许青. 重症监护病房肝移植受者的药物相关问题[J]. 中华移植杂志(电子版), 2023, 17(02): 104-111.
[7] 黄明珠, 陆鹰, 何康, 王艳. 儿童肝移植受者出院后服药依从性现状调查及影响因素分析[J]. 中华移植杂志(电子版), 2023, 17(02): 112-117.
[8] 邢建坤, 王菲, 王兢, 李云生, 吴迪, 陈晓敏, 杨磊, 李东毅, 孙丽莹, 朱志军. "图文式护理准备清单"在腹腔镜活体供肝获取术中的应用[J]. 中华移植杂志(电子版), 2023, 17(02): 118-123.
[9] 邢建坤, 王菲, 王兢, 李云生, 霍迎雪, 魏林, 刘思琦, 朱志军. 活体肝移植供者围手术期下肢深静脉血栓形成风险及优化策略[J]. 中华移植杂志(电子版), 2023, 17(01): 54-57.
[10] 蔡金贞. 儿童肝移植临床技术挑战[J]. 中华移植杂志(电子版), 2023, 17(01): 0-.
[11] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 中华医学会外科学分会移植学组, 中国医院协会器官获取与分配工作委员会. 中国心脏死亡捐献器官评估与应用专家共识(2022版)[J]. 中华移植杂志(电子版), 2022, 16(06): 321-328.
[12] 罗来邦, 王绪杨, 胡续光, 张友福, 徐志丹. 宏基因组二代测序早期筛查肝移植术后人类微小病毒B19感染临床研究[J]. 中华移植杂志(电子版), 2022, 16(06): 346-352.
[13] 王晓东, 汪恺, 葛昭, 丁忠祥, 徐骁. 计算机视觉技术在肝癌肝移植疗效提升中的研究进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 361-366.
[14] 中华医学会外科学分会外科手术学学组, 中华医学会外科学分会移植学组, 华南劈离式肝移植联盟. 劈离式肝移植血管分割与重建中国专家共识[J]. 中华肝脏外科手术学电子杂志, 2023, 12(02): 167-172.
[15] 卢强, 杨丽斐, 刘康, 余佳薇, 任璐, 张谞丰, 吕毅. 供肝免冲洗灌注的大鼠肝移植实验研究[J]. 中华肝脏外科手术学电子杂志, 2023, 12(01): 103-107.
阅读次数
全文


摘要